(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Black Diamond Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BDTX's revenue for 2026 to be $1,095,241,899, with the lowest BDTX revenue forecast at $1,095,241,899, and the highest BDTX revenue forecast at $1,095,241,899. On average, 3 Wall Street analysts forecast BDTX's revenue for 2027 to be $2,054,127,026, with the lowest BDTX revenue forecast at $731,286,322, and the highest BDTX revenue forecast at $3,931,507,773.
In 2028, BDTX is forecast to generate $10,479,895,522 in revenue, with the lowest revenue forecast at $2,418,870,142 and the highest revenue forecast at $14,626,851,496.